JP

John Parker

Principal at Tidal Capital Holdings

Greater Boston

Overview 

John Parker is a Managing Partner and Founder at Springhood Ventures, specializing in venture philanthropy and seed capital investments in companies focused on children's health. He has a strong track record of backing impactful startups like Nicolette and Stingray Therapeutics, contributing to their growth and success in the healthcare sector.

Work Experience 

  • Managing Partner, Founder

    2019 - Current

    Springhood backs Seed Stage life science and healthcare companies developing commercial solutions for important unmet medical needs of children.  These can include drugs, devices, diagnostics, and digital technologies that demonstrably improve health outcomes of pediatric patients. We expect to generate superior financial returns by identifying and investing in exceptional opportunities in the child health market, with its unique combination of high need, exceptional innovation, and incentivized development pathways.

Backing emerging companies tackling the biggest problems in children’s health

  • Board Observer

    2024

  • Managing Director, Founder

    2015

    CH Innovations makes program-related investments in young companies that seek to improve children's health and quality of life on behalf of the Charles H. Hood Foundation.

  • Vice President Board of Trustees; Investment Committee

    2008

  • Principal

    2002

    Private investment company

  • Board Observer

    2023

Plakous Therapeutics is a human biologics company that specializes in restorative and regenerative healing.

Raised $3,657,991.00 from Altis Biosystems, North Carolina Biotechnology Center, North Carolina Biotechnology Center, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), One North Carolina Small Business Program and The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

  • Board Observer

    2022

DeckTherapeutics specializes in acute omega-3 fatty acid therapeutics for neuroprotection.

  • Board Observer

    2022

  • Member Board of Directors

    2021

  • Board Observer

    2020

Articles About John

Relevant Websites